Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 15, Issue 1, Pages 53-58Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0b013e31814daf9b
Keywords
rheumatoid arthritis; tumor necrosis factor-alpha; disease-modifying antirheumatic drugs; rituximab; abatacept
Categories
Ask authors/readers for more resources
Significant advances have been made in the treatment of rheumatoid arthritis (RA). For instance, novel biologic therapeutics capable of blocking tumor necrosis factor-alpha (TNF-alpha) have improved outcomes for RA patients. New therapeutic agents directed at antagonizing two previously untargeted pathways have recently been approved by the U.S. Food and Drug Administration for RA patients who have had inadequate responses to anti-TNF therapy or who have failed to maintain an adequate clinical response. We review the data supporting the use of these agents, rituximab and abatacept.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available